Citadel Advisors
CSTL icon

Citadel Advisors’s Castle Biosciences CSTL Stock Holding History

Citadel Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,500
Closed -$307K – 13841
2026
Q1 		$307K Buy
+12,500
New +$409K ﹤0.01% 10420
2025
Q4 		– Sell
-9,300
Closed -$212K – 12839
2025
Q3 		$212K Buy
+9,300
New +$189K ﹤0.01% 11150
2025
Q2 		– Sell
-5,000
Closed -$100K – 12892
2025
Q1 		$100K Sell
5,000
-3,300
-40% -$81.7K ﹤0.01% 11463
2024
Q4 		$221K Buy
8,300
+2,400
+41% +$73.1K ﹤0.01% 10269
2024
Q3 		$168K Buy
5,900
+5,800
+5,800% +$148K ﹤0.01% 10404
2024
Q2 		$2.18K Buy
+100
New +$2.23K ﹤0.01% 13722
2024
Q1 		– Sell
-3,500
Closed -$75.5K – 14668
2023
Q4 		$75.5K Sell
3,500
-3,200
-48% -$56.3K ﹤0.01% 11290
2023
Q3 		$113K Buy
6,700
+5,600
+509% +$97.9K ﹤0.01% 10736
2023
Q2 		$15.1K Buy
1,100
+900
+450% +$18.2K ﹤0.01% 12965
2023
Q1 		$4.54K Sell
200
-5,900
-97% -$144K ﹤0.01% 13947
2022
Q4 		$144K Buy
+6,100
New +$141K ﹤0.01% 10674
2021
Q2 		– Sell
-4,800
Closed -$329K – 13756
2021
Q1 		$329K Sell
4,800
-7,500
-61% -$564K ﹤0.01% 10620
2020
Q4 		$826K Buy
12,300
+6,600
+116% +$358K ﹤0.01% 7190
2020
Q3 		$293K Buy
+5,700
New +$254K ﹤0.01% 8169

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's CSTL Position: Q2 2026 in Review

Citadel Advisors increased its Castle Biosciences (CSTL) stake by 119% in Q2 2026, buying an estimated $3.22M and bringing the position to 265,353 shares worth $6.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4313.

Citadel Advisors first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $22.2M in Q4 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Citadel Advisors held 265,353 shares of Castle Biosciences worth $6.33M as of Q2 2026.
  • Citadel Advisors bought 144,376 Castle Biosciences shares in Q2 2026, an estimated $3.22M.
  • Castle Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4313 holding.
  • Citadel Advisors first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Castle Biosciences position peaked at $22.2M in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.